Key result
Type 2 diabetes mellitus was associated with a lower 3-year survival free from sudden cardiac death (96.7% vs. 100%) in patients with hypertrophic cardiomyopathy who underwent septal myectomy.
Why the study?
Type 2 diabetes mellitus is linked to adverse outcomes after CABG and valve surgery, but its impact on midterm outcomes after septal myectomy for hypertrophic cardiomyopathy was unknown.
Does type 2 diabetes mellitus increase the risk of cardiovascular death or sudden cardiac death in patients with hypertrophic cardiomyopathy undergoing septal myectomy?
Cohort (n=201)
Yes
Does type 2 diabetes mellitus increase the risk of cardiovascular death or sudden cardiac death in patients with hypertrophic cardiomyopathy undergoing septal myectomy?
Type 2 diabetes mellitus is associated with a higher rate of sudden cardiac death in patients with hypertrophic cardiomyopathy following septal myectomy, suggesting a need for closer monitoring and potential ICD implantation.
T2DM may worsen midterm outcomes after septal myectomy in HCM; leaves open whether optimized glycemic control alters prognosis.
BACKGROUND: Type 2 diabetes mellitus is common in cardiovascular disease. It is associated with adverse clinical outcomes for patients who had undergone coronary artery bypass and valve operations. The aim of this study was to evaluate the impact of type 2 diabetes mellitus on the midterm outcomes of patients with hypertrophic cardiomyopathy who underwent septal myectomy. METHODS: We retrospectively analyzed the data of 67 hypertrophic cardiomyopathy patients with type 2 diabetes mellitus who underwent septal myectomy from two medical centers in China from 2011 to 2018. A propensity score-matched cohort of 134 patients without type 2 diabetes mellitus was also analyzed. RESULTS: During a median follow-up of 28.0 (interquartile range: 13.0-3.0) months, 9 patients died. The cause of death of all of these patients was cardiovascular, particularly sudden cardiac death in 3 patients. Patients with type 2 diabetes mellitus had a higher rate of sudden cardiac death (4.5% vs. 0.0%, p = 0.04). The Kaplan-Meier survival analysis revealed that the rates of predicted 3-year survival free from cardiovascular death (98.1% vs. 95.1%, p = 0.14) were similar between the two groups. However, the rates of predicted 3-year survival free from sudden cardiac death (100% vs. 96.7%, p = 0.01) were significantly higher in hypertrophic cardiomyopathy patients without type 2 diabetes mellitus than in those with type 2 diabetes mellitus. Furthermore, after adjustment for age and sex, only N-terminal pro-brain natriuretic peptide (hazards ratio: 1.002, 95% confidence interval: 1.000-1.005, p = 0.02) and glomerular filtration rate ≤ 80 ml/min (hazards ratio: 3.23, 95% confidence interval: 1.34-7.24, p = 0.047) were independent risk factors for hypertrophic cardiomyopathy patients with type 2 diabetes mellitus. CONCLUSIONS: Hypertrophic cardiomyopathy patients with and without type 2 diabetes mellitus have similar 3-year cardiovascular mortality after septal myectomy. However, type 2 diabetes mellitus is associated with higher sudden cardiac death rate in these patients. In addition, N-terminal pro-brain natriuretic peptide and glomerular filtration rate ≤ 80 ml/min were independent risk factors among hypertrophic cardiomyopathy patients with type 2 diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) conducted a cohort in Hypertrophic obstructive cardiomyopathy (n=201). Type 2 diabetes mellitus vs. No type 2 diabetes mellitus was evaluated on 3-year survival free from sudden cardiac death (p=0.01). Type 2 diabetes mellitus was associated with a lower 3-year survival free from sudden cardiac death (96.7% vs. 100%) in patients with hypertrophic cardiomyopathy who underwent septal myectomy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: